Addiction to Oncogenes--the Achilles Heal of Cancer

  title={Addiction to Oncogenes--the Achilles Heal of Cancer},
  author={I. Weinstein},
  pages={63 - 64}
A series of recent studies are providing tantalizing hints of new therapeutic approaches for combating cancer. In his Perspective, Weinstein discusses new work ( Jain et al.) demonstrating that even brief inactivation of an oncogene can permanently reverse the malignant phenotype of some types of tumor. 

Topics from this paper

Cancer revoked: oncogenes as therapeutic targets
  • D. Felsher
  • Biology, Medicine
  • Nature Reviews Cancer
  • 2003
Recent findings show that even the brief inactivation of a single oncogene might be sufficient to result in the sustained loss of a neoplastic phenotype. It is therefore possible that the targetedExpand
Pharmacological Intervention With Multistep Oncogenesis
The first part of this chapter reviews current challenges involved in attacking multistep oncogenesis and discusses the consequences for therapeutic and chemopreventive strategies, highlighting inExpand
Oncogene addiction: role of signal attenuation.
It is reported that "oncogene addiction" may be mediated by differential rates of signal attenuation of proapoptotic and prosurvival pathways. Expand
mTOR and cancer: reason for dancing at the crossroads?
  • G. Thomas
  • Biology, Medicine
  • Current opinion in genetics & development
  • 2006
There is an urgent need to translate basic scientific findings into relevant, clinically applicable molecular diagnostic assays for the treatment of cancers through the molecular characterization of the tumors. Expand
BIM, PUMA, and the Achilles’ Heel of Oncogene Addiction
Because resistance mechanisms often emerge, explicating the pathways that connect therapeutic oncogene inactivation to the cell death machinery is critical to exploiting additional synthetic lethal opportunities. Expand
Oncogene Addiction in Solid Tumors
This chapter aims to summarize the recent evidences concerning the concept of oncogene addiction and describes molecular mechanisms that could explain this phenomenon. Expand
Addicted to Myc--but why?
An essential role for endogenous Myc proteins in maintaining the tumor microenvironment is demonstrated, providing an unexpected molecular explanation for addiction to Myc. Expand
Cancer: An unexpected addiction
Both oncogenes and normal genes can mediate the development and progress of cancer. What used to separate their effects was cancer's dependence on, or 'addiction' to, oncogenes but not normal genes.Expand
Oncogene addiction.
The efficacy of molecular targeted therapy requires novel methods, including integrative genomics and systems biology, to identify the state of oncogene addiction (i.e., the "Achilles heel") in specific cancers. Expand
Oncogene addiction: sometimes a temporary slavery.
Tumors induced in conditional oncomice can show remarkable different responses to subsequent oncogene deprivation, and these models reflect many of the features seen in human cancer and can therefore assist in understanding the underlying mechanisms and in designing more effective treatment protocols. Expand


Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC
It is demonstrated that brief inactivation of MYC results in the sustained regression of tumors and the differentiation of osteogenic sarcoma cells into mature osteocytes, raising the possibility that transient in activation ofMYC may be an effective therapy for certain cancers. Expand
Cancer gene therapy: fringe or cutting edge?
Direct targeting of cancer cells with gene therapy has the potential to treat cancer on the basis of its molecular characteristics. But although laboratory results have been extremely encouraging,Expand
Reversible tumorigenesis by MYC in hematopoietic lineages.
It is concluded that even though tumorigenesis is a multistep process, remediation of a single genetic lesion may be sufficient to reverse malignancy. Expand
Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis.
It is hypothesized that homeostatic feedback mechanisms play a critical role in multistage carcinogenesis, and agents that increase cellular levels of p27(Kip1) may, therefore, also be useful in cancer therapy. Expand
Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion.
It is shown that activation of c-MycER in adult suprabasal epidermis rapidly triggers proliferation and disrupts differentiation of postmitotic keratinocytes, changes that resemble hyperplastic actinic keratosis, a commonly observed human precancerous epithelial lesion. Expand
The Hallmarks of Cancer
This work has been supported by the Department of the Army and the National Institutes of Health, and the author acknowledges the support and encouragement of the National Cancer Institute. Expand
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
It is found that drug resistance is associated with the reactivation of BCR-ABL signal transduction in all cases examined and a strategy for identifying inhibitors of STI-571 resistance is suggested. Expand
Suppression of Myc-Induced Apoptosis in β Cells Exposes Multiple Oncogenic Properties of Myc and Triggers Carcinogenic Progression
The data indicate that highly complex neoplastic lesions can be both induced and maintained in vivo by a simple combination of two interlocking molecular lesions. Expand
Transient excess of MYC activity can elicit genomic instability and tumorigenesis.
  • D. Felsher, J. Bishop
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1999
It is suggested that the accelerated passage through G1 was mutagenic but that the effect of MYC permitted a checkpoint response only after G2 had been reached, suggesting that MYC may contribute to tumorigenesis through a dominant mutator effect. Expand
c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations
It is demonstrated that c-MYC-induced mammary tumorigenesis proceeds through a preferred secondary oncogenic pathway involving Kras2, suggesting that secondary mutations in ras contribute to tumor progression. Expand